News

Dana-Farber/Boston Children’s researcher is part of a new Stand Up To Cancer campaign with Marvel Studios’ Avengers and American Airlines

Today, Stand Up To Cancer (SU2C), American Airlines and Marvel Studios’ Avengers: Infinity War announced a powerful collaboration as they team up in the fight against cancer.

Bursting with gene therapies and other innovative treatments, the overall survival rate for our blood and marrow transplant patients is exceeding expectations

Dana-Farber/Boston Children's is the only pediatric stem cell transplant center in the U.S. to exceed expected outcomes for allogeneic transplant patients in 2017.

A new gene therapy transplantation technique could improve treatment of neurodegenerative disease

Alessandra Biffi, MD, led a study that shows the efficacy of a new gene therapy transplantation technique that could have future applications for treating neurodegenerative diseases.

Two Dana-Farber/Boston Children's faculty members elected to National Academy of Medicine

Two Dana-Farber/Boston Children's Cancer and Blood Disorders Center faculty members, Scott Allen Armstrong, MD, PhD, and Scott Pomeroy, MD, PhD, have been elected to the National Academy of Medicine (NAM).

Gene therapy halts progression of cerebral adrenoleukodystrophy in clinical trial

The devastating neurodegenerative disease typically affects young boys and causes death within 10 years

Dana-Farber/Boston Children's responds to FDA approval of CAR-T cell therapy

The FDA's approval of CAR-T therapy for refractory pediatric and young adult ALL underscores the potential of CAR T-cell therapies, a form of cancer immunotherapy, to treat a wide range of cancers, researchers say.

Novel CRISPR-Cas9 genetic screening approach enables discovery of new drug targets to aid cancer immunotherapy

A novel screening method, using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice, has revealed new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.

Dana-Farber/Boston Children's again named a top national pediatric cancer program

U.S. News & World Report has ranked Dana-Farber/Boston Children's Cancer and Blood Disorders Center the nation's #2 pediatric cancer program in its new 2017-18 Best Children's Hospitals report.

Gene Therapy 2.0

Levi Looks, diagnosed through newborn screening with “bubble boy” disease, is a healthy toddler thanks to gene therapy, resurgent now after early setbacks, MIT Technology Review reports.

How dogs may help fight bone cancer

In the growing field of comparative oncology, veterinarians are teaming up with oncologists to study the similarities in human and canine cancer to boost cure rates for people and pets alike, CBS Sunday Morning reports.